Bordeaux

• Randomized controlled multicenter study comparing steroid therapy plus anticoagulants to steroid therapy alone in deep venous thrombosis of … Recruiting
  2023-510262-27-00 4 2025-06-24 newly diagnosed or relapsing deep venous thrombosis related to Behçet’
• Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associa … Recruiting
  2024-516243-81-00 5 2025-06-23 myelin oligodendrocytes glycoprotein antibody associated diseases (MOG
• A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren’s diseas … Recruiting
  2024-514596-18-00 9 2025-06-20 Difficult to treat rheumatoid arthritis
• ​​Master Protocol of Novel Study Interventions and Combinations in Participants with Colorectal Cancer​ Recruiting
  2024-518469-84-00 4 2025-06-20 ​​Colorectal cancer​
• A Phase 1/2a Study of BMS-986507 (BL-B01D1) in Adult Participants with Advanced Solid Tumors Recruiting
  2024-514947-27-00 9 2025-06-18 Advance solid tumors
• A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated wit … Recruiting
  2023-505834-84-00 10 2025-06-17 relapsed and refractory primary diffuse large B-cell lymphoma of the C
• JAK inhibitor dose TAPering strategy study in low disease activity rheumatoid arthritis patients. Recruiting
  2023-509788-25-00 6 2025-06-16 Rheumatoid arthritis
• Evaluation of 200 mg of Rituximab every 6 months as maintenance treatment of Rituximab-treated patients with rheumatoid arthritis: a non-inf … Recruiting
  2024-519991-18-00 6 2025-06-16 Rheumatoid Arthritis
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient … Recruiting
  2023-510026-32-00 5 2025-06-11 Generalized Myasthenia Gravis
• A clinical study to assess the safety and efficacy of oral ART0380 as a single agent or in combination in solid tumors Recruiting
  2024-511534-12-00 7 2025-06-10 Advanced or Metastatic Solid Tumours
• A Study of ORX750 in Subjects with Narcolepsy and Idiopathic Hypersomnia Recruiting
  2024-518929-15-00 4 2025-06-09 Narcolepsy and Idiopathic Hypersomnia
• REscue of Nephrons with ALe.F02 (RENAL F02) Recruiting
  2022-502184-38-00 4 2025-06-06 Rapidly progressive glomerulonephritis
• A clinical study of V940 and BCG in people with bladder cancer (V940-011) Recruiting
  2024-517335-46-00 4 2025-06-05 Bladder cancer
• A Study to Determine Safety and Long-Term Effectiveness of Faricimab in Participants with Age-Related Macular Degeneration Recruiting
  2024-517545-13-00 11 2025-06-04 Neovascular Age-Related Macular Degeneration
• Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke Recruiting
  2023-506935-14-01 5 2025-06-01 Ischemic stroke
• An open-label extension study to assess the efficacy and safety of ianalumab with or without study treatment withdrawal in adult participan … Recruiting
  2024-515280-60-00 5 2025-05-29 Lupus nephritis
• Blocage de l'interféron-ɣ par le ruxolitinib pour le traitement de la myosite à inclusion : un essai de phase IIb Recruiting
  2023-507666-32-00 4 2025-05-27 Inclusion body Myositis
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 5 2025-05-23 Metastatic hormone naïve prostate cancer (mHNPC)
• Long-term study evaluating joint health in people with haemophilia A receiving real-world prophylactic treatment with efanesoctocog alfa Recruiting
  2024-517812-31-00 6 2025-05-21 Haemophilia A
• A study to find how well Dazodalibep works and how safe it is in participants with Sjôgren`s Syndrome Recruiting
  2024-517513-32-00 5 2025-05-16 Sjögren’s Syndrome
• Efficacy of daily IV administration of dornase alfa for up to 14 days post subarachnoid haemorrhage on functional independence at 6 months: … Recruiting
  2023-509627-40-01 5 2025-05-15 subarachnoid hemorrhage
• Interventional, multicenter, open-label, randomized, non-comparative trial evaluating the safety, in terms of HBV virological control, of 2 … Recruiting
  2023-508634-34-00 4 2025-05-14 co-infected with the HIV-1 and HBV viruses
• A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia Recruiting
  2024-519822-18-00 10 2025-05-14 Narcolepsy Type 1, Type 2 and Idiopathic Hypersomnia

Showing 313–336 of 1,096 trials